LifeVantage (LFVN) AI Stock Analysis

190 Followers

Top Page

LifeVantage

(NASDAQ:LFVN)

70Outperform

LifeVantage shows strong financial performance, demonstrated by improved margins and robust cash flow. The earnings call reveals positive growth but also highlights some challenges, particularly in international markets. Technical indicators suggest some caution is warranted due to bearish signals. The valuation remains reasonable, providing a balanced view of potential risks and rewards.

LifeVantage (LFVN) vs. S&P 500 (SPY)

Market Cap

$165.91M

Dividend Yield1.19%

Average Volume (3M)203.94K

Price to Earnings (P/E)19.2

Beta (1Y)-0.17

Revenue Growth8.22%

EPS Growth159.71%

CountryUS

Employees222

SectorConsumer Defensive

Sector Strength72

IndustryPackaged Foods

Share Statistics

EPS (TTM)0.26

Shares Outstanding12,588,183

10 Day Avg. Volume275,026

30 Day Avg. Volume203,945

Financial Highlights & Ratios

PEG Ratio0.26

Price to Book (P/B)4.87

Price to Sales (P/S)0.00

P/FCF Ratio11.61

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$30.00

Price Target Upside127.62% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

LifeVantage Business Overview & Revenue Model

Company DescriptionLifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. The company offers Protandim, a line of scientifically validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support digestive system health; a line of weight management products under the PhysIQ brand; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a line of energy drink mixes. It also provides anti-aging skin care products, including facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, the company offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website, as well as through a network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and China. LifeVantage Corporation is headquartered in Lehi, Utah.

How the Company Makes MoneyLifeVantage makes money primarily through direct sales and a multi-level marketing (MLM) business model. Revenue is generated from the sale of its nutraceutical and personal care products to both independent distributors and retail customers. The company's distributors purchase products at a wholesale price and sell them at retail prices, earning commissions based on their sales volume. Additionally, distributors are incentivized to recruit new members into their sales network, which can further drive sales and increase commission opportunities. LifeVantage also leverages various partnerships and collaborations to expand its market reach and enhance product distribution, contributing to its revenue streams.

LifeVantage Financial Statement Overview

Summary

LifeVantage demonstrates strong cash flow management, a solid balance sheet, and efficient cost management. However, revenue growth inconsistency and modest profit margins suggest areas for improvement.

Income Statement

Positive

The TTM gross profit margin is strong at 79.78%, indicating efficient cost management. However, the net profit margin stands at a modest 3.46%, suggesting room for improvement in controlling other expenses. Revenue growth has been inconsistent, with a slight decline recently. EBIT and EBITDA margins are moderate, reflecting average operational efficiency.

Balance Sheet

Positive

The company maintains a healthy equity ratio of 43.61%, indicating good financial stability and asset management. The debt-to-equity ratio is 0.43, demonstrating conservative leverage. Return on equity is modest at 24.56%, suggesting a decent return on shareholders’ investments.

Cash Flow

Positive

The operating cash flow to net income ratio is robust at 1.95, showing strong cash generation relative to net income. Free cash flow growth is positive, and the free cash flow to net income ratio of 1.75 suggests healthy cash flow management supporting business operations.

TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Breakdown
Income Statement		Total Revenue
212.15M	200.16M	213.40M	206.36M	220.18M	232.91M
	Gross Profit
169.27M	158.72M	170.01M	168.26M	181.99M	194.95M
	EBIT
10.84M	4.33M	4.26M	1.86M	11.42M	9.68M
	EBITDA
14.15M	7.93M	4.26M	9.75M	23.07M	19.88M
	Net Income Common Stockholders
7.34M	2.94M	2.54M	3.12M	12.89M	11.55M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
21.59M	16.89M	21.61M	20.19M	23.17M	22.14M
	Total Assets
68.53M	60.30M	66.12M	70.71M	78.73M	58.88M
	Total Debt
12.77M	13.61M	13.09M	15.76M	18.18M	1.18M
	Net Debt
-8.83M	-3.27M	-8.52M	-4.43M	-4.99M	-20.95M
	Total Liabilities
38.64M	34.31M	31.47M	39.19M	41.92M	25.62M
	Stockholders Equity
29.89M	25.99M	34.65M	31.52M	36.81M	33.25M
Cash Flow		Free Cash Flow
12.88M	9.95M	3.76M	6.43M	12.53M	15.64M
	Operating Cash Flow
14.29M	12.20M	6.83M	7.96M	16.27M	18.33M
	Investing Cash Flow
-1.41M	-2.25M	-3.06M	-1.53M	-3.73M	-2.68M
	Financing Cash Flow
-8.43M	-14.42M	-2.36M	-8.95M	-11.45M	-12.42M

LifeVantage Technical Analysis

Technical Analysis Sentiment

Neutral

Last Price13.18

Price Trends

50DMA

13.96

Negative

100DMA

16.81

Negative

200DMA

14.25

Negative

Market Momentum

MACD

-0.33

Negative

RSI

52.51

Neutral

STOCH

90.58

Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFVN, the sentiment is Neutral. The current price of 13.18 is above the 20-day moving average (MA) of 12.27, below the 50-day MA of 13.96, and below the 200-day MA of 14.25, indicating a neutral trend. The MACD of -0.33 indicates Negative momentum. The RSI at 52.51 is Neutral, neither overbought nor oversold. The STOCH value of 90.58 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LFVN.

LifeVantage Risk Analysis

LifeVantage disclosed 50 risk factors in its most recent earnings report. LifeVantage reported the most risks in the “Finance & Corporate” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

LifeVantage Peers Comparison

Overall Rating

UnderperformOutperform

Sector (64)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NATR	77 Outperform	$273.06M	27.80	6.42%	―	2.00%	-37.09%
USNA	73 Outperform	$560.00M	16.47	6.78%	―	-2.69%	-43.24%
SENEA	71 Outperform	$630.67M	16.67	6.35%	―	4.01%	22.46%
LFVN	70 Outperform	$165.91M	19.18	30.11%	1.19%	8.22%	159.71%
Sector *	64 Neutral	$8.82B	14.70	4.78%	173.90%	3.26%	2.11%
HLF	62 Neutral	$705.80M	2.52	-31.74%	―	-2.45%	100.59%
HAIN	43 Neutral	$186.82M	―	-31.83%	―	-8.50%	-186.18%

* Consumer Defensive Sector Average

Performance Comparison

LFVN

LifeVantage

13.18

6.10

86.16%

HLF

Herbalife

6.93

-3.97

-36.42%

NATR

Nature's Sunshine Products

14.88

-0.20

-1.33%

SENEA

Seneca Foods

91.46

30.63

50.35%

HAIN

Hain Celestial

2.07

-5.20

-71.53%

USNA

USANA Health

30.07

-18.57

-38.18%

LifeVantage Earnings Call Summary

Earnings Call Date:May 06, 2025

(Q3-2025)

% Change Since: 10.11%|

Next Earnings Date:Aug 14, 2025

Earnings Call Sentiment Neutral

The earnings call highlighted significant revenue growth and profitability improvements driven by the successful U.S. launch of the MindBody GLP1 system and ongoing international expansion. However, challenges in international markets and prior stock-out issues have moderated the outlook, leading to a reduced revenue forecast.

Q3-2025 Updates

Positive Updates

Revenue Growth

LifeVantage reported third quarter revenues of $58.4 million, marking a 21% increase year-over-year. U.S. revenues grew 31% year-over-year, driven by strong demand for the MindBody GLP1 system.

Profitability Improvements

Adjusted EBITDA increased 27% year-over-year to $6.4 million, with an adjusted EBITDA margin improvement of 50 basis points to 11%. Gross margin also improved by 210 basis points to 81%.

Active Accounts and Subscriptions

Active accounts increased by 17% in the Americas, with a 13% increase in independent consultants and a 19% increase in customers. Subscription orders showed strong growth, with global active templates increasing by over 10,000.

International Expansion

LifeVantage began the international expansion of the MindBody system in Japan, Australia, New Zealand, Mexico, the UK, Europe, and Thailand, with momentum building in these markets.

Successful Product Launch

The launch of the MindBody GLP1 system in the U.S. in October 2024 has been a success with significant sales growth. The product is also being introduced in international markets with promising initial results.

Positive Clinical Study Results

A clinical study revealed that the MindBody GLP1 system increased GLP1 levels in the body by over 200% on average, validating its effectiveness.

Negative Updates

International Revenue Decline

Revenue in international markets decreased by 7% year-over-year, with challenges particularly noted in the Asia Pacific and Europe regions.

Stock-Out Issues

LifeVantage faced stock-out issues with the MindBody GLP1 system after its U.S. launch, affecting customer and consultant satisfaction and contributing to a sequential decline in active accounts.

Lower Revenue Outlook

The company reduced its revenue guidance for fiscal 2025 due to continued challenges in international markets and uncertainties surrounding the international rollout of the MindBody system.

Company Guidance

During the call, LifeVantage provided guidance for fiscal year 2025, projecting revenues between $228 million and $235 million, representing a 16% increase at the midpoint compared to fiscal 2024. The company aims for adjusted EBITDA between $21 million and $24 million, and adjusted non-GAAP earnings per share ranging from $0.72 to $0.88. Additionally, LifeVantage anticipates maintaining strong profitability metrics, including a gross margin of 81% and an effective tax rate of approximately 22% to 24%. The company also highlighted the successful introduction of the MindBody GLP1 system in international markets, which is expected to further drive growth.

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.